|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
IRCT |
|
Last refreshed on:
|
22 February 2018 |
|
Main ID: |
IRCT2016052528070N1 |
|
Date of registration:
|
2016-06-21 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Effect of SMS on carrying out the blood test in a timely manner in AF patients
|
|
Scientific title:
|
Assess the effect of SMS to carrying out the INR test in a timely manner and Clinical Decision Support System on improving guideline adherence in the treatment of atrial fibrillation |
|
Date of first enrolment:
|
2016-06-21 |
|
Target sample size:
|
400 |
|
Recruitment status: |
Complete |
|
URL:
|
http://en.irct.ir/trial/22849 |
|
Study type:
|
interventional |
|
Study design:
|
Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive.
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Iran (Islamic Republic of)
| | | | | | | |
|
Contacts
|
|
Name:
|
Dr Saeed Eslami
|
|
Address:
|
Medical college
Mashhad
Iran (Islamic Republic of) |
|
Telephone:
|
+98 51 3841 2081 |
|
Email:
|
EslamiS@mums.ac.ir |
|
Affiliation:
|
Mashhad University of Medical Sciences |
|
|
Name:
|
Reza Sheibani
|
|
Address:
|
Medical college
917794-8564
Mashhad
Iran (Islamic Republic of) |
|
Telephone:
|
+98 51 3882 8888 |
|
Email:
|
sheibanir911@mums.ac.ir |
|
Affiliation:
|
Mashhad University of Medical Sciences |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: Newly diagnosed AF that must take warfarin with outpatient follow-up will be included. Patients will be excluded from the study when they or their families do not have mobile phones for sending SMS.
Exclusion criteria:
Age minimum:
no limit
Age maximum:
no limit
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Atrial fibrillation and flutter
|
Atrial fibrillation.
Atrial fibrillation and flutter
|
|
Intervention(s)
|
|
Control group will not receive any reminder
|
|
Intervention group will receive SMS reminder for INR test and physicians will use CDSS
|
|
Treatment - Drugs
|
|
Intervention 1: Intervention group will receive SMS reminder for INR test and physicians will use CDSS. Intervention 2: Control group will not receive any reminder.
|
|
Prevention
|
|
Primary Outcome(s)
|
|
Percent time in therapeutic INR range. Timepoint: With each patient visit. Method of measurement: Therapeutic INR range for newly diagnosed AF patient is 2.0-3.0.
|
|
Carrying out the INR test in a timely manner. Timepoint: With each patient visit. Method of measurement: Compare the date on which the test must be done with a date that has been really done.
|
|
Secondary Outcome(s)
|
|
Mortality. Timepoint: At least nine months later in the follow-up period. Method of measurement: number of events.
|
|
Thromboembolic events. Timepoint: At least nine months later in the follow-up period. Method of measurement: Number of events.
|
|
Bleeding. Timepoint: At least nine months later in the follow-up period. Method of measurement: number of events.
|
|
Source(s) of Monetary Support
|
|
Mashhad University of Medical Sciences
|
|
Ethics review
|
Status: Approved
Approval date:
Contact:
Mashhad University of Medical Sciences
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|